Recent Findings from Shanghai University of Traditional Chinese Medicine Has Provided New Information about Type 2 Diabetes (Phenylacetylglutamine As a Novel Biomarker of Type 2 Diabetes With Distal Symmetric Polyneuropathy By Metabolomics).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      SHANGHAI (China)
    • Abstract:
      A recent study conducted by researchers at Shanghai University of Traditional Chinese Medicine has identified phenylacetylglutamine (PAG) as a potential biomarker for type 2 diabetes mellitus (T2DM) with distal symmetric polyneuropathy (DSPN). The study analyzed plasma samples from healthy controls, T2DM patients, and DSPN patients using metabolomics. The results showed that PAG levels were significantly higher in the DSPN group compared to the control and T2DM groups, suggesting its potential as a biomarker for DSPN. Further research is needed to understand the role of PAG in the pathogenesis of DSPN. [Extracted from the article]
    • Abstract:
      Copyright of Diabetes Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)